Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N2O2 |
Molecular Weight | 352.4699 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=LKYQLAWMNBFNJT-UHFFFAOYSA-N
InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/13815278
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278
Aniledrine is a narcotic pain reliver. The drug was prescribed as an analgesic in anaesthesia (Leritine brand name), however, it is no longer available on the market. Although the exact mechanism is not fully understood, aniledrine appears to elicit its action by binding to endorphine receptors in CNS.
CNS Activity
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13815278 |
Curative | LERITINE Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
450 mg multiple, oral (total daily dose|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: Page: p.319 |
unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: Page: p.319 |
Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium Sources: Page: p.319 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Delirium | Disc. AE | 450 mg multiple, oral (total daily dose|max) Studied dose Dose: 450 mg Route: oral Route: multiple Dose: 450 mg Sources: Page: p.319 |
unhealthy, 41 n = 1 Health Status: unhealthy Condition: Pain Age Group: 41 Sex: M Population Size: 1 Sources: Page: p.319 |
PubMed
Title | Date | PubMed |
---|---|---|
Contact dermatitis to anileridine. | 1980 Dec |
|
Qualitative differences in effects of opioids in man: preliminary evidence for multiple mechanisms of analgesic action. | 1986 May |
|
Anileridine-induced delirium. | 1995 May |
|
Electronic-topological study of the structure-activity relationships in a series of piperidine morphinomimetics. | 2002 Aug |
|
Metabolic fate of orally administered phyllodulcin in rats. | 2004 Sep |
|
Synthesis, characterization and antimicrobial properties of a Co(II)-phthalylsulfathiazolate complex. | 2010 Dec |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
9020
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
||
|
WHO-ATC |
N01AH05
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
||
|
WHO-VATC |
QN01AH05
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8022610
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
Anileridine
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201347
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
144-14-9
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
220
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
17933
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB05514MIG
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
C100232
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
61203
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
8944
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
100000086945
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
m1921
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
C65234
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
DB00913
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
7115
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
71Q1A3O279
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
528
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY | |||
|
3288
Created by
admin on Sat Dec 16 16:54:43 GMT 2023 , Edited by admin on Sat Dec 16 16:54:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)